[CUR] Neuralstem, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.31 Change: 0.02 (8.21%)
Ext. hours: Change: 0 (0%)

chart CUR

Refresh chart

Strongest Trends Summary For CUR

CUR is in the medium-term up 38% in 2 months and down -74% below S&P in 1 year. In the long-term down -88% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company?s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI?566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company?s clinical development products also comprise NSI?566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI?189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40% Sales Growth - Q/Q-40% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-70.66% ROE-112.4% ROI-82.24%
Current Ratio6.72 Quick Ratio Long Term Debt/Equity0.28 Debt Ratio0.22
Gross Margin Operating Margin-93733.3% Net Profit Margin-120900% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.89 M Cash From Investing Activities-100 K Cash From Operating Activities-4.72 M Gross Profit
Net Profit-5.05 M Operating Profit-4.61 M Total Assets30.8 M Total Current Assets29.15 M
Total Current Liabilities4.34 M Total Debt8.88 M Total Liabilities11.44 M Total Revenue
Technical Data
High 52 week1.9 Low 52 week0.3 Last close0.47 Last change-9.25%
RSI53.6 Average true range0.05 Beta0.73 Volume457.73 K
Simple moving average 20 days2.44% Simple moving average 50 days15.41% Simple moving average 200 days-49.31%
Performance Data
Performance Week-14.91% Performance Month26.54% Performance Quart-2.59% Performance Half-61.47%
Performance Year-69.87% Performance Year-to-date50.14% Volatility daily6.21% Volatility weekly13.89%
Volatility monthly28.46% Volatility yearly98.6% Relative Volume618.32% Average Volume182.88 K
New High New Low

News

2019-02-07 07:00:00 | Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

2018-12-18 07:00:00 | Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

2018-12-04 05:00:00 | Germantown biotech faces stock delisting threat

2018-11-27 10:22:20 | How Financially Strong Is Neuralstem Inc NASDAQ:CUR?

2018-11-19 07:55:00 | Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US — Emerging Consolidated Expectations, Analyst Ratings

2018-11-14 17:00:00 | Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-10-26 09:00:00 | Neuralstem Announces $2.1 Million Registered Direct Offering

2018-10-25 07:00:00 | Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell NSC Transplantation in a Mouse Model of Alzheimer’s Disease 

2018-09-18 11:20:37 | Should You Have Neuralstem Inc’s NASDAQ:CUR In Your Portfolio?

2018-08-15 10:24:24 | Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

2018-08-09 07:00:00 | Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

2018-08-07 14:41:23 | Germantown biopharma Neuralstem appoints interim CEO

2018-08-06 07:00:00 | Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

2018-08-01 09:05:46 | CORRECTING and REPLACING -- Neuralstem, Inc.

2018-08-01 09:01:56 | Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

2018-07-31 18:14:42 | Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke

2018-07-23 11:50:21 | Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

2018-06-12 08:00:00 | Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

2018-06-11 07:00:00 | Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

2018-06-04 07:00:00 | Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete paraplegia

2018-05-29 07:00:00 | Neuralstem to Participate at the BIO 2018 International Convention

2018-05-15 07:00:00 | Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

2018-05-03 07:00:00 | Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

2018-04-18 07:00:00 | Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation

2018-04-11 08:30:00 | Today’s Research Reports on Trending Tickers: Neuralstem and Immunomedics

2018-04-11 07:00:00 | Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

2018-04-10 07:00:00 | Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

2018-04-02 07:30:00 | Neuralstem Reports Year End 2017 Fiscal Results and Business Update

2018-03-13 07:00:00 | Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury 

2018-03-12 07:00:00 | Neuralstem to Participate at Upcoming Investor Conferences

2018-02-08 07:00:00 | Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium

2018-01-22 07:00:00 | Neuralstem to Participate at Cell and Gene Therapy World

2018-01-05 17:25:55 | Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology

2017-12-26 11:25:27 | ETFs with exposure to Neuralstem, Inc. : December 26, 2017

2017-12-20 07:30:00 | New Member appointed to the Board of Directors of Neuralstem

2017-12-08 08:20:00 | Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.

2017-12-07 13:26:54 | ETFs with exposure to Neuralstem, Inc. : December 7, 2017

2017-12-06 08:00:00 | Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.

2017-12-06 07:53:00 | 800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock

2017-12-05 12:57:44 | Neuralstem, Inc. CUR: Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm

2017-12-05 07:00:00 | Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology ACNP Annual Meeting

2017-11-30 11:45:08 | Does Neuralstem Inc’s CUR Past Performance Indicate A Stronger Future?

2017-11-16 16:05:00 | Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

2017-11-13 07:41:27 | Neuralstem reports 3Q loss

2017-11-13 07:30:00 | Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update

2017-11-10 12:10:11 | ETFs with exposure to Neuralstem, Inc. : November 10, 2017

2017-11-09 08:59:43 | Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

2017-11-08 07:30:00 | Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

2017-10-17 17:31:32 | One Thing To Consider Before Buying Neuralstem Inc CUR

2017-09-27 08:05:00 | Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells